BridgeMD
New treatment option for Obsessive-Compulsive Disorder
Official title Individually Targeted Neuromodulation for Contamination-based OCD
ClinicalTrials.gov ID: NCT05048251
What this study is testing
- What it's testing
- Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- male or female age 18-55 years old
- DSM-5 diagnosis of OCD as primary presenting disorder
- CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is the highest score on the Dimensional Yale-Brown Obsessive...
- score of ≥ 8 on Dimension 4 of the D-YBOCS
- taking no psychiatric medications or on a stable dose of an SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks prior...
You likely can't join if
- positive urine drug screen (other than prescribed benzodiazepines)
- use of psychiatric medications other than permitted above
- substance use disorder in the last 3 months (with the exception of nicotine)
- history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and past history of depressive, anxiety, and eating disorders...
- active suicidal ideation over the week prior to screening (as indicated by answering yes to questions 1 or 2 on the C-SSRS)
- history of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease
See the full eligibility criteria
- male or female age 18-55 years old
- DSM-5 diagnosis of OCD as primary presenting disorder
- CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is the highest score on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS); participants with more than one Dimension as...
- score of ≥ 8 on Dimension 4 of the D-YBOCS
- taking no psychiatric medications or on a stable dose of an SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks prior to enrollment. Use of PRN benzodiazepines will be permitted as long as...
- have not initiated a new course of exposure and response prevention (ERP) therapy within 4 weeks of enrollment (ongoing ERP will be permitted if initiated more than 8 weeks before enrollment).
- positive urine drug screen (other than prescribed benzodiazepines)
- use of psychiatric medications other than permitted above
- substance use disorder in the last 3 months (with the exception of nicotine)
- history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and past history of depressive, anxiety, and eating disorders permitted as long as OCD is considered the primary disorder)
- active suicidal ideation over the week prior to screening (as indicated by answering yes to questions 1 or 2 on the C-SSRS)
- history of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease
- pregnancy or lactating
- contraindication to MRI scanning or TMS
The study team makes the final eligibility decision.
Where it's taking place
- Belmont, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belmont, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.